Globe Newswire

Phoenix, AZ, June 06, 2024 (GLOBE NEWSWIRE) -- The LifeNet, Native Air, and TriState CareFlight programs across Arizona are proud to announce they now carry and can administer whole blood onboard every air medical transport via helicopter. These programs are all part of Air Methods, the leading air medical service provider in the nation. Having whole blood aboard their helicopters allows their industry-leading trauma clinicians to provide additional life-saving care... (continue reading...)

Toronto, Ontario, June 06, 2024 (GLOBE NEWSWIRE) -- TVO Media Education Group (TVO) is thrilled to announce eight significant wins at the 2024 Canadian Screen Awards, which took place between May 28-31 in Toronto, Canada. The nature-themed docuseries The Water Brothers was honoured alongside beloved TVOkids series All-Round Champion, Wild Kratts and PAW Patrol.

“Everyone at TVO is overjoyed to see the Academy of Canadian Cinema and Television recognize the... (continue reading...)

SAN CARLOS, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Oportun (Nasdaq: OPRT), a mission-driven fintech, today announced that it will participate in the upcoming Sidoti June Virtual Investor Conference.

Oportun’s Chief Executive Officer, Raul Vazquez, and Chief Financial Officer & Chief Administrative Officer, Jonathan Coblentz, will present and participate in investor meetings at the conference. The presentation will begin at 4:00 pm ET on June 12th and can be... (continue reading...)

REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively. The Company... (continue reading...)

REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively. The Company... (continue reading...)